VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment

Thrombosis Research

Volumn 123, Issue SUPPL. 1, 2008, Pages

  Lee, Agnes ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ARTICLE; BLEEDING; BREAST CANCER; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ECHOGRAPHY; GLIOMA; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; NEOPLASMS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 55249088483     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.017     Document Type: Article

References (26)

1. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., and Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24 (2006) 484-490
2. Stein P.D., Beemath A., Meyers F.A., Skaf E., Sanchez J., and Olson R.E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119 (2006) 60-68
3. Blom J.W., Vanderschoot J.P., Oostindier M.J., Osanto S., van der Meer F.J., and Rosendaal F.R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4 (2006) 529-535
4. Chew H.K., Wun T., Harvey D., Zhou H., and White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006) 458-464
5. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
6. Semrad T.J., O'Donnell R., Wun T., Chew H., Harvey D., Zhou H., et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106 (2007) 601-608
7. Sorensen H.T., Mellemkjaer L., Olsen J.H., and Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000) 1846-1850
8. Sorensen H.T., Mellemkjaer L., Steffensen F.H., Olsen J.H., and Nielsen G.L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism [see comments]. N Engl J Med 338 (1998) 1169-1173
9. Lee A.Y., Julian J.A., Levine M.N., Weitz J.I., Kearon C., Wells P.S., et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 131 (1999) 417-423
10. Carrier M., Lee A.Y., Bates S.M., Anderson D.R., and Wells P.S. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. J Thromb Haemost 5 Suppl 2 (2007) PS-555
11. Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (2008) 387-394
12. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double- blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 84 (1997) 1099-1103
13. Bergqvist D., Agnelli G., Cohen A.T., Eldor A., Nilsson P.E., Moigne-Amrani A., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
14. Agnelli G., Bolis G., Capussotti L., Scarpa R.M., Tonelli F., Bonizzoni E., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243 (2006) 89-95
15. Francis C.W. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 356 (2007) 1438-1444
16. Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer [see comments]. Lancet 343 (1994) 886-889
17. Haas S.K., Kakkar A.K., Kemkes-Matthes B., Freund M., Gatzemeier U., Heilmann L., von Tempelhoff G.F., Brom J., and Weidinger G. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer - results of the TOPIC Studies. J Thromb Haemost 3 Suppl 1 (2005) abstract #OR059
18. Perry J.R., et al., for the Ontario Clinical Oncology Group and PRODIGE Investigators. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 25 18S (2007) abstract #2011
19. Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
20. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 401S-428S
21. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
22. Deitcher S.R., Kessler C.M., Merli G., Rigas J.R., Lyons R.M., and Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12 (2006) 389-396
23. Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R., et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 120 (2007) 72-82
24. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
25. Noble S.I.R., and Finlay I.G. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19 (2005) 197-201
26. Akl E.A., van Doormaal F.F., Barba M., Kamath G., Kim S.Y., Kuipers S., et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev (2007) CD006652